Skip to content
The Tuberous Sclerosis Association Logo The Tuberous Sclerosis Association Logo
FacebookTwitterLinkedInAmazon SmileAmazon SmileTelephoneTelephone
Tel:
0300 222 5737
  • I NEED SUPPORT
  • DONATE
  • SHOP
  • Information & support
    • TSC overview
      • What is TSC?
      • Diagnosis
      • TSC and genetics
      • Treatment and management
    • Get help and support
      • Contact our support team
      • Carer information and support
      • How to be referred to an NHS TSC clinic
        • Find a local NHS TSC clinic
      • Access benefits and financial aid
    • How TSC affects the body
      • Physical effects
        • Epilepsy
        • Brain
        • Heart
        • Lungs
        • Skin
        • Eyes
        • Kidneys
        • Other areas
      • Wider effects (TAND)
        • Intellectual ability
        • TSC-Associated Neuropsychiatric Disorders (TAND)
        • Sleep problems
  • Life with TSC
    • Living with TSC
      • TSC stories
      • New diagnosis
      • Living well
      • Siblings
      • Holiday and leisure
      • Education
      • Housing
    • TSC at different life stages
      • Early years and childhood
      • Adolescents and transition to adult life
      • Adult life
      • End of life and bereavement
  • For professionals
    • Professionals
      • Healthcare professionals
        • UK TSC clinical guidelines
        • Personal Child Health Record (Red book)
        • Advice on medicines
      • Social care professionals
      • Education professionals
    • TSC conferences
      • International TSC Research Conference 2020
    • Educational materials
      • BMJ learning modules
      • Belfast TAND conference
  • Research
    • How we deliver research
      • Research strategy
      • TSA-funded research
      • TSC research volunteer network
      • Meet your research committee
      • Common questions about our research
    • TSA researchers
      • Research opportunities
      • TSC research from other groups
    • TSC conferences
      • International TSC research conference 2020
  • Get involved
    • Our community events
      • Big Day
      • Scottish Get Together
      • Northern Ireland Study Day
      • Outlook
      • Welsh Info Day
      • Family Fun Day
    • Donate
      • Donate to the TSA
      • Gift Aid
      • How your donations help
      • Corporate partnerships and giving
      • Give in remembrance or celebration
      • Leave a legacy
    • Fundraise
      • Take part in a fundraising event
      • Organise your own fundraising event
      • TSA fundraising campaigns
        • Tea & SCones for TSC
        • Jeans for Genes
        • Christmas
      • Pay in your fundraising
      • Fundraising champions
    • Join the conversation
      • Share your story or expertise
      • Community groups and other groups
  • About the TSA
    • Keep updated
      • News and campaigns
      • TSA Blog
      • All TSA events
      • Newsletters and TSA magazine (SCAN)
    • About us
      • Mission and vision
      • Meet your team
      • History of the TSA
      • Annual reports
    • Contact us
      • Click here to talk to us
Previous Next

TSA Research: Forthcoming trial of topical sirolimus for facial angiofibromas in TSC

A facial rash, or facial angiofibromas, is one of the symptoms experienced by many people with TSC. One of the treatments for this is topical sirolimus (rapamycin) – an ointment that is applied directly to the rash. As topical sirolimus is not yet licensed by the European Medicines Agency, funding is not routinely available for it to be prescribed to patients in the UK.    
The TSA gets lots of enquiries about topical sirolimus and we know just how important this is to so many of you. So, we are investing in providing the right resources for you about facial angiofibromas and topical sirolimus.

Globally there is growing evidence of the success of using topical sirolimus. This has largely been based on evidence derived from case reports and case series. Although there has been some trial work in the USA, Australia and Japan, that has shown that topical sirolimus is safe to use in patients and resulted improvement of facial angiofibromas. 
We are working towards starting a UK scientific trial looking at the effectiveness of topical sirolimus, within the next 12-18 months. In the meantime, some areas of the UK – the TSC Clinic at the Royal United Hospital in Bath, and, Great Ormond Street Hospital, London, have had some success in being able to prescribe the cream and are reporting good results using it with their patient populations.  
Dr Lea Solman, Fellow in Paediatric Dermatology, Great Ormond Street Hospital, London shares her experiences of using topical sirolimus in the Summer 2017 edition of Scan, page 18.  
And Dr Sam Amin, Research Associate in Tuberous Sclerosis Complex at Bath TSC Clinic, Royal United Hospital, Bath, explains how he has been prescribing the cream, and its successes to date, in the Summer 2017 edition of Scan, on page 19.

You can also watch a video interview between the TSA’s Emma Damian-Grint and Dr Sam Amin and Dr Chris Kingswood about the forthcoming trial of topical sirolimus for facial angiofibromas HERE.

And here is a scientific research poster on the same subject.{module_literature filter=”item” itemId=”143614″}If you are interested in taking part in the forthcoming trial, or would like to share your experiences to date in trying to access topical sirolimus for facial angiofibroma in TSC, then please email research@tuberous-sclerosis.org or talk to your local TSA Adviser.

The TSA2017-06-16T00:00:00+00:00

Share this post

FacebookTwitterLinkedInRedditWhatsappEmail

Useful links

  • TSC overview
  • Get support
  • Shop

Policies

  • Compliments and complaints
  • Event terms and conditions
  • Fundraising promise
  • Privacy Policy
  • Report an issue
  • Safeguarding
  • Shop terms of sale
  • Sitemap
  • Volunteer policy
  • Vulnerable supporter policy
  • Website terms and disclaimer

Follow us

  • Facebook
  • Twitter
  • Linkedin
  • News

Contact Us

The TSA
Unit 56,
1 Emma Street,
London, E2 9FP


admin@tuberous-sclerosis.org

0300 222 5737

© 2019 The Tuberous Sclerosis Association.
The Tuberous Sclerosis Association is a company limited by guarantee. Registered in England and Wales no. 2900107.
Charity no. 1039549 (England & Wales) SC042780 (Scotland). Website design by DIG Online.

The Tuberous Sclerosis Association